Success didn’t come overnight, but ten years after its founding, Umeå-based HILICON has built a solid presence in 40 countries. The company is making its mark in the chromatography industry with consistent revenue growth and innovative products in the pipeline.
“My dream is to double the turnover in a few years,” says Wen Jiang, CEO and founder of HILICON.
MetaCurUm Biotech AB has been awarded one million SEK from the Swedish Innovation Agency, Vinnova, under the “Acceleration of Deeptech Companies 2024” initiative.
“This support is crucial for us as it brings us closer to securing additional funding that will help us advance to clinical trials,” says CEO Maarten de Château.
From December 2-13, Daniel Pacurar, an eco-tech innovator from northern Sweden, will join global leaders in Riyadh, Saudi Arabia, for UNCCD COP16, a climate conference focused on combating drought and desertification. Daniel has been invited to hold a seminar to present his innovative re:moss concept.
“With the help of the re:moss concept and technology, we aim to support the countries and regions facing these challenges,” says Daniel, Founder and Executive Chairman of Boreal Orchards.
Umeå-based Medicvent is seeking a new CEO as Erik Lindström transitions to a new role within the parent group, Sdiptech.
Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC).
“This approval is a significant step forward in our global growth strategy”, states Jean Lycke, Project Manager at Mucocort AB.
The city of Umeå is actively seeking life science companies interested in setting up operations in the region. Partnering with Umeå Biotech Incubator, the municipality sends a delegation to BIO-Europe – Europe’s largest life science conference – to forge new connections and promote Umeå’s strengths as a life science hub.
The European sunflower market is facing challenges and seeking new solutions. Cropcision, a Swedish startup, has the potential to contribute to this evolving landscape. Their plastic-free precision fertilizers will be tested in a sunflower trial, supported by EIT Food, in Spain in 2025.
Sofia Mayans, who transitioned from her research to co-founding the award-winning company InfiCure Bio, is taking on a new role as Director of Business Development at Diamyd Medical in Umeå.
“With our in-house expertise and the new production facility coming online, Diamyd Medical has significant business opportunities ahead,” she says.
QureTech Bio has received a substantial investment from Kempestiftelserna. A total of SEK 14 million is invested in the company by Kempestiftelserna along with the company’s largest shareholder, Nascent Invest.
Urban Eriksson has been appointed as the new Chairman of the board for Umeå Biotech Incubator.
Two business coaches from Umeå Biotech Incubator will head to the Nordic Life Science Days in Malmö on September 18-19. Their schedule is already packed with 22 pre-arranged meetings with a range of investors and potential partners for UBI’s 17 ongoing cases.
“We’ve lined up meetings with a mix of new and established contacts, both from Sweden and internationally,” say Pia Keyser and Tobias Tovedal.
For seriously ill children and adolescents, intravenous drip stands can significantly hinder mobility. Umeå based Nil Medical has developed an ergonomic medical vest that conceals fluids, pumps, and tubing within the garment, allowing for unrestricted play and movement.
A national quality-of-life study is underway, in collaboration with Swedish healthcare, and Nil Medical aims to introduce the vest to the international market.
Swedish biotech company AlexoTech set a new turnover record in 2023 and predicts another strong performance this year. Citing Agrisera as a local role model, CEO and founder Anders Olofsson believes there are plenty of opportunities for Umeå based AlexoTech to expand.
Umeå based QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, has appointed Markus Thor as the new Chief Executive Officer.
“Along with the team, I will strive to bring our substances to clinical trials”, he states.
On June 17th, Boreal Orchards delivered their first batch of moss primer to Kiruna as part of the re:moss project. That same day, the EU Council adopted the Nature Restoration Law, the first comprehensive, continent-wide legislation of its kind. The law sets binding targets and obligations for EU member states to rehabilitate at least 20 percent of the EU’s land and sea areas by 2030 and all degraded ecosystems by 2050.
QureTech Bio AB, a biotech company that develops novel antibiotics, has announced the appointment of Lennart Hansson as its new Chairman of the Board. Hansson succeeds Sven Bergström, who is stepping down after a successful tenure leading the company’s strategic direction.
Cryptosporidiosis is one of the biggest threats to newborn calves in the global agricultural industry. It is also responsible for hundreds of thousands of human deaths in developing countries each year.
There is currently no effective treatment for the disease, but a new case at UBI is set to change that. Professor Christian Hedberg is developing a new drug with the potential to revolutionize the treatment of cryptosporidiosis worldwide.
Umeå based HiloProbe has raised an additional SEK 3 Million in funding from existing owners. This capital injection is a step towards achieving the next goal.
Umeå is strengthening its position as a life science hub thanks to two regional development projects receiving around €1.8 million (22 SEK million) in EU support. These projects aim to boost innovation, collaboration, and industry growth.
“This presents an opportunity to further elevate Umeå’s standing as a life science leader,” emphasizes Peter Jacobsson, Operations Coordinator at Umeå Biotech Incubator (UBI).
Mattias Forsell, Johan Normark and Julia Wigren Byström, the founders of the UBI Alumni Xerum AB, have been awarded Umeå University’s and Nordea’s Innovation Prize for utilisation 2024. This is for the successful COVID-19 research conducted by a clinician, a preclinical researcher, and a biomedical analyst.